Azeliragon in MGMT Unmethylated Glioblastoma
Clinical trial NCT05986851 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05986851
- Sponsor
- Cantex Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-09-12
- Primary completion
- 2026-09-30
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.